Quick Answer
Liminatus Pharma, Inc. reported Operating Income Loss of -$2.97 million for the year ending 2025.
- Liminatus Pharma, Inc. showed an increase of +10.9% in Operating Income Loss from 2024 to 2025.
- This data is from Liminatus Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: -$2.97 million | Fiscal year 2024: -$3.33 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: